Agios Pharmaceuticals (NASDAQ:AGIO) Announces Earnings Results

Agios Pharmaceuticals (NASDAQ:AGIO) released its earnings results on Thursday. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, beating the consensus estimate of ($1.24) by $0.15, FiscalAI reports. Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 35.67%. The firm had revenue of $55.39 million during the quarter, compared to analyst estimates of $51.65 million.

Here are the key takeaways from Agios Pharmaceuticals’ conference call:

• Agios reported record third-quarter revenue of $55.4 million, more than four times the year-ago quarter, with $48.7 million from U.S. sales. The company attributed growth to AQVESME’s thalassemia launch and said U.S. revenue rose 20% sequentially.
• The FDA’s request for additional information on whether a REMS is needed for mitapivat in sickle cell disease extended the review by three months, moving the PDUFA goal date to February 1, 2027. Agios said it is discussing labeling and potential REMS elements with the agency and remains launch-ready.
• AQVESME had 619 completed start forms since launch—about 15% of Agios’s roughly 4,000-patient target population—with another 48 in process. The company reported approximately 75% of patients remained on therapy at six months and said demand is broadening to community practices and non-transfusion-dependent patients.
• Agios highlighted upcoming sickle cell data on sustained hemoglobin responses and post-hoc kidney and cardiac measures, while noting the organ findings are exploratory. It also expects to present AG-236 healthy-volunteer data at ASH, including effects lasting through six months, and plans to begin its PV phase II/III program by year-end.
• Agios ended the quarter with $907 million in cash and expects 2026 operating expenses to remain approximately flat year over year, excluding specified one-time items. It plans to reduce R&D headcount by more than 35% during 2026, with savings expected in 2027, and is targeting non-GAAP profitability in 2028.

Agios Pharmaceuticals Trading Up 4.0%

Shares of Agios Pharmaceuticals stock opened at $29.41 on Friday. Agios Pharmaceuticals has a twelve month low of $22.24 and a twelve month high of $46.00. The business’s fifty day moving average price is $33.27 and its 200 day moving average price is $31.76. The stock has a market capitalization of $1.76 billion, a P/E ratio of -4.65 and a beta of 0.66.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Truist Financial decreased their price objective on Agios Pharmaceuticals from $37.00 to $35.00 and set a “buy” rating for the company in a report on Friday. Weiss Ratings reiterated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Monday, September 21st. Citigroup upped their price target on Agios Pharmaceuticals from $46.00 to $52.00 and gave the company a “buy” rating in a report on Friday, July 31st. TD Cowen raised Agios Pharmaceuticals to a “strong-buy” rating in a research report on Monday, August 24th. Finally, HC Wainwright increased their target price on shares of Agios Pharmaceuticals from $55.00 to $62.00 and gave the stock a “buy” rating in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Agios Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $42.12.

More Agios Pharmaceuticals News

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: Q3 results beat expectations: Agios reported a loss of $1.09 per share, narrower than analyst estimates, while revenue of $55.39 million topped the $51.65 million consensus. The per-share loss also improved from $1.78 a year earlier. Agios Q3 results and business update
• Positive Sentiment: Mitapivat growth and regulatory milestone: Mitapivat revenue increased more than fourfold, and an FDA decision on the drug for sickle-cell disease is expected in February 2027. Strong sales and a potential approval could support future growth, though the FDA outcome remains uncertain. Mitapivat revenue and FDA timeline
• Positive Sentiment: HC Wainwright raised its target: The firm lifted its price target from $55 to $62 and maintained a Buy rating, signaling substantial expected upside from the cited share price. HC Wainwright recommendations
• Neutral Sentiment: Truist lowered its target but kept a Buy rating: Truist cut its target from $37 to $35, while continuing to see upside from the cited price. The reduction tempers, but does not reverse, its positive stance. Truist recommendations
• Negative Sentiment: Planned R&D workforce reductions: Agios aims to eliminate more than 100 R&D roles. Cuts could reduce costs, but may also raise concerns about research capacity and execution as the company approaches a key regulatory decision. Agios R&D job cuts

Insider Buying and Selling

In other Agios Pharmaceuticals news, insider Sarah Gheuens sold 7,866 shares of Agios Pharmaceuticals stock in a transaction on Monday, October 26th. The shares were sold at an average price of $37.69, for a total transaction of $296,469.54. Following the completion of the sale, the insider owned 54,645 shares of the company’s stock, valued at approximately $2,059,570.05. The trade was a 12.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 9,855 shares of company stock worth $371,112. 5.40% of the stock is owned by corporate insiders.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering and developing medicines for rare diseases involving cellular metabolism. The company’s research is centered on metabolic pathways that influence red blood cell production and function, with the goal of addressing conditions that have limited treatment options.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase. Pyrukynd is approved in the United States and other markets for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency, a rare inherited blood disorder.